Kairos Pharma, LTD. - Form 8-K Summary
Business Context and Reporting Period
Company: Kairos Pharma, LTD.
Filing Date: September 11, 2025
Reporting Period: Current Report (Event Date: September 11, 2025)
Business Focus: Biopharmaceutical company developing treatments for advanced prostate cancer.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a corporate event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes or operational updates were reported in this filing. The document solely announces a scheduled corporate event.
Outlook, Management Commentary, and Risks
- Upcoming Event: The Company will host a Key Opinion Leader (KOL) event on Thursday, September 18, 2025, at 5 p.m. ET / 2 p.m. PT.
- Event Topic: Discussion of diverse perspectives on interim efficacy results from a Phase 2 trial of the lead candidate, ENV105, for treating advanced prostate cancer.
- Legal Disclaimer: Information in Item 8.01 and Exhibit 99.1 is furnished, not "filed" under Section 18 of the Exchange Act, and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the date and time of the KOL event (September 18, 2025).
- Review the attached Press Release (Exhibit 99.1) for specific details on the Phase 2 interim efficacy results for ENV105.
- Confirm the trading symbol (KAPA) and exchange (NYSE American) for the Common Stock.
- Note that this filing does not constitute an admission of materiality regarding the event details.